Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1999;84:647-654

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mano, T.
Right arrow Articles by Walsh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mano, T.
Right arrow Articles by Walsh, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Carotid Artery Disease
Related Collections
Right arrow Gene expression
Right arrow Smooth muscle proliferation and differentiation
(Circulation Research. 1999;84:647-654.)
© 1999 American Heart Association, Inc.


Original Contribution

Reversal of GATA-6 Downregulation Promotes Smooth Muscle Differentiation and Inhibits Intimal Hyperplasia in Balloon-Injured Rat Carotid Artery

Toshiaki Mano, Zhengyu Luo, Slawomir L. Malendowicz, Todd Evans, Kenneth Walsh

From the Division of Cardiovascular Research (T.M., Z.L., K.W.), St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass; the Department of Medicine, Division of Cardiology (S.L.M.), and the Department of Developmental and Molecular Biology (S.L.M., T.E.), Albert Einstein College of Medicine, Bronx, NY.

Correspondence to Kenneth Walsh, PhD, Division of Cardiovascular Research, St. Elizabeth's Medical Center, Tufts University School of Medicine, 736 Cambridge St, Boston, MA 02135. E-mail kwalsh{at}opal.tufts.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—The GATA-6 transcription factor is expressed in quiescent vascular smooth muscle cells (VSMCs) in culture, and levels of its transcript are rapidly downregulated on mitogen stimulation. In this study, we demonstrate that the GATA-6 transcript, protein, and DNA-binding activity are downregulated in rat carotid arteries on balloon injury. Downregulation was detected at 1 and 3 days after injury and recovered by 7 days. To assess the role of GATA-6 downregulation in injury-induced vascular lesion formation, adenoviral vectors were used to express wild-type human GATA-6 cDNA (Ad-GATA6) or an inactive mutant cDNA that lacks a portion of the zinc-finger domain (Ad-GATA6{Delta}ZF). Adenovirus-mediated GATA-6 gene transfer to the vessel wall after balloon injury partially restored the levels of GATA-6 protein and DNA-binding activity to before injury levels. The local delivery of Ad-GATA6 but not Ad-GATA6{Delta}ZF inhibited lesion formation by 46% relative to saline control and 50% relative to a control adenovirus that expressed lacZ. Local delivery of Ad-GATA6 also reversed changes in the expression patterns of smooth muscle myosin heavy chain, smooth muscle {alpha}-actin, calponin, vinculin, metavinculin, and proliferating cell nuclear antigen that are associated with injury-induced VSMC phenotypic modulation. These data indicate that the injury-induced downregulation of GATA-6 is an essential feature of VSMC phenotypic modulation that contributes to vessel lesion formation.


Key Words: gene expression • adenovirus • restenosis • muscle, smooth • genes


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Vascular injury provokes the proliferation of medial VSMCs, which migrate to the intima and produce extracellular matrix.1 These processes are believed to contribute to restenotic lesions that occur after balloon angioplasty and are of particular importance in the development of lesions within stents2 and bypass grafts.3 Several studies have shown that overexpression of cell-cycle inhibitory genes can inhibit intimal lesion formation in animal models of vascular injury, which indicates that this approach may have use in the treatment of fibroproliferative diseases of the vessel wall.4 However, little is known about the endogenous regulators of VSMC phenotype that control the transition from a quiescent, differentiated cell under normal conditions to a proliferative, dedifferentiated cell in the presence of pathological stimuli.

The GATA family of transcriptional regulatory proteins includes 6 vertebrate genes, which each contain a highly conserved zinc-finger DNA-binding domain that interacts with DNA regulatory elements that contain a consensus A/T GATA A/G (WGATAR) or related sequence. The vertebrate GATA factors are categorized into 2 subfamilies. Each of the GATA-1/2/3 genes is essential for a distinct function in hematopoietic cell development,5 whereas the GATA-4/5/6 genes are each expressed in cells of the cardiovascular system and endoderm-derived tissues, including the gut.5 GATA-4 can affect cardiogenesis in vitro,6 7 and it can regulate cardiac muscle–specific gene expression by transactivating promoters that contain the GATA consensus binding site.8 9 10 In vivo, GATA-4/5/6 can activate muscle-specific genes,11 although its primary functions are more firmly established in the regulation of embryonic morphogenesis in mouse12 13 and chick.14 Additional data from the frog system also suggest that GATA-6 can play a role in regulating cell proliferation during cardiogenesis.11 Although the expression patterns for the GATA-4/5/6 genes largely overlap during early embryogenesis, GATA-6 transcript levels are particularly high in the developing cardiac outflow tract.12 13 Expression patterns for GATA-4 and GATA-6 diverge with the onset of vasculogenesis; only GATA-6 is expressed in the medial smooth muscle cells of the vasculature.15 Although its function in smooth muscle is undefined, GATA-6 appears to be the major GATA factor expressed in cultured VSMCs.15 16 By analogy to related family members, GATA-6 is likely to regulate the differentiation state of VSMCs in vivo.

Previously, we reported on GATA-6, the primary structure of the human protein, localized the chromosomal location to 18q11.1–18q11.2 and described the tissue-restricted transcription pattern in human tissues.16 We also demonstrated that GATA-6 is expressed in quiescent rat and human VSMCs in culture and that mitogen activation of these cultures led to a rapid and transient downregulation of expression with kinetics similar to that exhibited by gas and gadd genes.17 18 These data suggested that GATA-6 might function to coordinate the expression of VSMC-contractile genes with genes required for cell-cycle progression. Recently, we also demonstrated that plasmid-mediated overexpression of GATA-6 inhibits mitogen-induced cell cycle activity in VSMCs and fibroblasts in vitro.19 Therefore, GATA-6 is an excellent candidate for a lineage-restricted regulatory protein that can regulate VSMC phenotype in proliferative lesions of the vessel wall.

In this study, we examined the regulation and function of GATA-6 during the proliferative response of VSMCs to acute injury. Balloon injury of adult rat carotid arteries results in rapid VSMC loss due to apoptotic cell death20 followed by the temporally and spatially coordinated initiation of the cell cycle in the remaining VSMCs.21 VSMCs that proliferate then migrate to the lumen and form a neointimal lesion by 2 weeks.22 In this study, we show that GATA-6 is downregulated during the peak of proliferative activity after balloon injury. To determine the functional significance of this downregulation, adenovirus-mediated GATA-6 gene transfer to balloon-injured rat carotid arteries was performed, which resulted in restoration of GATA-6 expression. Although before injury levels were not achieved, vessels transduced with the GATA-6–encoding adenovirus displayed a higher degree of VSMC differentiation and a reduced level of intimal hyperplasia. These data suggest that GATA-6 controls VSMC phenotype in vivo and that suppression of this factor may contribute to the pathogenesis of VSMC-derived lesions.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cell Lines
Rat primary VSMCs (passage<5) were obtained by enzymatic digestion of the media from the thoracic aorta of male Sprague-Dawley rats23 and maintained in DMEM with 15% FBS. Synchronous populations of quiescent cells were obtained by placing cultures in media that contained 0.5% FBS for 48 to 72 hours. VSMCs were infected with adenovirus at the indicated multiplicity of infection (MOI) for 12 hours, followed by virus removal and incubation in low-mitogen media for 12 more hours. Growth media (15% FBS) was then added for 24 hours. NIH3T3 and 10.1 fibroblasts were infected with adenovirus in media that contained 0.5% FBS for 12 hours, followed by incubation with DMEM that contained 10% FBS for 36 hours.

Adenoviral Vector Construction
A cDNA encoding the full-length human GATA-6 protein was isolated from pCDNA-GATA-6wt19 and inserted into the KpnI-XbaI sites of pACCMV.pLpA, which contains a CMV promoter/enhancer, SV40 polyA tract, and the Ad5 adenoviral sequences required for homologous recombination to generate the plasmid pACCMV.pLpA-GATA-6wt. A cDNA that contained a deletion in the zinc-finger region, which results in expression of a protein that lacks codons 244 to 306, was subcloned similarly into pACCMV.pLpA to generate pACCMV.pLpA-GATA-6-{Delta}ZF. Each plasmid and pJM17 was cotransfected into 293 cells, which allowed for homologous recombination.24 The E1-/E3-deleted adenovirus constructs that contained GATA-6wt (Ad-GATA6) or GATA-6-{Delta}ZF (Ad-GATA6-{Delta}ZF) were purified from isolated plaques, identified by polymerase chain reaction (PCR) and immunoblotting analysis, and amplified in 293 cells. The viral preparations used for both in vitro and in vivo studies were purified by CsCl gradient ultracentrifugation and dialyzed against buffer, which contained 10 mmol/L Tris-HCl and 10% glycerol. The titer of recombinant adenoviruses was determined by plaque assay on 293 cells as described previously25 and expressed as plaque-forming units (PFU)/mL. The replication-defective adenoviral construct Ad-ßgal expresses ß-galactosidase from the CMV promoter.

Rat Model of Balloon Injury and Adenoviral Infection
The rat carotid artery balloon-injury model was based on a model described by Clowes et al.22 Adult male Sprague-Dawley rats that weighed 400 to 600 g were subjected to a distending, deendothelializing injury with an inflated 2F Fogarty embolectomy catheter inserted through the external carotid artery. The injured segment of artery was then incubated in the absence or presence of adenovirus (1.0x109 PFU) in a total volume of 100 µL saline for 20 minutes. Rats were killed at 1, 3, or 14 days after injury with an intraperitoneal injection of pentobarbitol (100 mg/kg). The balloon-injured segment of the artery from the proximal edge of the omohyoid muscle to the carotid bifurcation was perfused with saline and dissected. The tissue was then fixed with 100% methanol and embedded in paraffin. Histological images of 4 µmol/L cross sections from the center of the injured segment were hematoxylin-eosin or elastic-trichrome stained and used to determine the intimal, medial, and luminal areas by quantitative morphometric analysis with a computerized sketching program (MACMEASURE version 1.9). Three sections from each artery were evaluated by an investigator who was blinded to the identities of the treatment groups. Experimental protocol was approved by the Institutional Animal Care and Use Committee of St. Elizabeth's Medical Center and complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Cell-Cycle Analysis
Primary cultures of rat VSMCs were infected at a MOI of 300 PFU per cell with Ad-ßGAL, Ad-GATA6{Delta}ZF, or Ad-GATA6 for 12 hours, after which the virus was removed and cultures were incubated in low-mitogen media for an additional 12 hours. Growth media was then added for 24 hours, and cells were harvested by trypsinization, fixed, and stained with propidium iodide.26 Quiescent cells were harvested after 72 hours in low-mitogen media without infection. DNA content was analyzed by flow cytometry, and the cell-cycle profile was determined with a Beckton Dickinson Vantage flow cytometer and Lysis II cell cycle analysis software.

Immunoblot Analysis
Cells were infected with the indicated adenovirus at an MOI of 100 (NIH3T3 and 10.1 cells) or 300 (rat VSMCs) as described above. Whole cell extracts from rat carotid arteries and cultured cells were prepared in ice-cold lysis buffer (1% NP-40, 9.1 mmol/L dibasic sodium phosphate, 1.7 mmol/L monobasic sodium phosphate, 150 mmol/L NaCl, 1 mmol/L DTT, 0.5 mmol/L PMSF, 2 µg/mL aprotinin, 2 µg/mL leupeptin, 1 mmol/L sodium orthovanadate) and then centrifuged. Arterial extracts were prepared from a pool of 4 or 5 arteries with a homogenizer (Tissumizer Mark II; Tekmar Co). Immunoblot analyses used rabbit polyclonal antibody against human GATA-6 protein, as described previously,19 mouse monoclonal anti–proliferating cell nuclear antigen (PCNA; Signet Laboratories, Dedham, Mass), rabbit polyclonal anti-Cdk4 (C22, Santa Cruz, Calif), mouse monoclonal anti–smooth muscle myosin (hSM-V), mouse monoclonal anticalponin (hCP), mouse monoclonal antivinculin (hVIN-1; Sigma) and mouse monoclonal anti–{alpha}-tubulin (Calbiochem). Arterial segments were harvested at 24 hours, 72 hours, 7 days, and 14 days after balloon injury and treatment, and contralateral carotid arteries were taken as uninjured control arteries. Western immunoblot analyses were preformed on 10 to 75 µg of carotid artery extract protein, which depended on signal intensity as described previously.19 All immunoblot experiments were performed on at least 3 separate occasions.

Electrophoretic Mobility Shift Assays
Whole-cell lysates were prepared from rat carotid arteries, NIH3T3 cells, or 10.1 fibroblasts that were uninfected or infected with the indicated adenoviral construct in ice-cold lysis buffer (50 mmol/L Hepes, pH 7.8; 420 mmol/L KCl; 0.1 mmol/L EDTA, pH 8.0; 5 mmol/L MgCl2; 20% glycerol; 1 mmol/L DTT; 0.5 mmol/L PMSF; 2 µg/mL aprotinin; 2 µg/mL leupeptin; and 1 mmol/L sodium orthovanadate) by subjecting tissue or cells to 3 cycles of freezing and thawing followed by centrifugation. Double-stranded oligonucleotide probes and competitor DNAs were synthesized to correspond to the extensively characterized GATA consensus site in the {alpha}-globin promoter.15 The coding strand sequence for each probe was

GATA 5'-GATCTCCGGCAACTGATAAGGATTCCCTG-3'

GATA mt 5'-GATCTCCGGCAACTAGCTAGGATTCCCTG-3'

The consensus and mutated GATA-binding sites are underlined. Electrophoretic mobility shift assays (EMSAs) were performed as described previously.19 Supershift assays were performed with rabbit polyclonal anti–GATA-6 antibody or preimmune serum.19 All EMSA experiments were performed on at least 3 separate occasions.

RNA Isolation and Reverse Transcription–PCR Analysis on Balloon-Injured Rat Carotid Arteries
Individual arteries were isolated from each rat and immediately frozen in liquid nitrogen. For each sample, the tissue was transferred to a 50-mL polypropylene tube that contained 2 mL of TRI reagent (MRC) and homogenized with a hand-held tissue-tearer (Biospec Products). RNA was isolated after extraction by isopropanol precipitation. After the nucleic acids were washed in 70% ethanol, they were resuspended and the DNA was removed by digestion with 1 U of RQ1 RNAse-free DNAse (Promega Corp) for 10 minutes at 37°C. RNA was purified by phenol-chloroform extraction, precipitated by ethanol, and resuspended in H2O. RNA concentration was determined by optical density and then diluted to 0.1 mg/mL.

Each RNA sample was reverse-transcribed at 37°C for 1 hour in a 20-µL reaction that contained 100 pmol/L random hexamer pdN6 (Pharmacia) and 40 U murine leukemia virus reverse transcriptase (Gibco/BRL). Under standard conditions, each sample contained 0.5 µg of RNA. In some control experiments, 0.25 µg of RNA was used to ensure that the signal generated by PCR quantitatively reflected the RNA added. For PCR, 2 µL of each reverse transcription (RT) reaction was used in a 20-µL reaction, which contained 1.5 mmol/L MgCl2, 1.0 mmol/L concentration of each primer, 200 µmol/L dNTPs, and 0.1 µL of {alpha}32P-dCTP as a tracer for qualifying the products. Primer sequences were

GATA-6, forward: 5'-CCC AGC GCA GAC CTG TTG GAG GAC C

GATA-6, reverse: 5'-TGT GAC AGT TGG CAC AGG ACA G

GAPDH, forward: 5'-GAT GGT GAA GGT CGG TGT CAA

GAPDH, reverse: 5'-CAC CAC CTT CTT GAT GTC ATC

Cycling parameters for each primer pair were analyzed independently in preliminary experiments. Products were shown to accumulate linearly in accordance with cycle number and were directly dependent on the amount of RNA added to in the RT reaction. Each PCR was initiated with a 2-minute denaturing incubation at 95°C and ended with a 10-minute extension at 72°C. The cycle parameters were 30 seconds at 95°C, 45 seconds at 58°C, and 45 seconds at 72°C. The number of cycles used for GATA-6 and GAPDH was 26 and 24, respectively. Products were separated by electrophoresis in 5% polyacrylamide nondenaturing gels. Phosphorimage analysis was performed with a Molecular Dynamics Storm 860 phosphorimaging system to quantify the relative levels of GATA-6 and GAPDH PCR product.

Statistical Analysis
Results were expressed as the mean±SEM. In the fluorescence-activated cell sorter (FACS) analyses, statistical significance was evaluated by ANOVA followed by Scheffé's procedure. In the RT-PCR analysis, statistical significance was analyzed at the 3-day time point, the nadir of GATA-6 downregulation, with a paired Student t test. Statistical significance was assumed when the probability of a null hypothesis was <0.05.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Levels of GATA-6 Gene Products and DNA Binding Activity Are Decreased After Injury in Rat Carotid Arteries
To investigate the regulation of GATA-6 during VSMC proliferation in vivo, adult male rats were subjected to a balloon injury with a catheter inserted through the external carotid artery. At various times after injury, protein extracts or RNA were prepared from isolated arteries and control contralateral uninjured arteries and samples were analyzed for GATA-6 levels. Immunoblot analyses were performed with a specific antiserum against GATA-6 to assess changes in GATA-6 protein expression during the proliferative response. The expression of GATA-6 protein markedly decreased at 1 and 3 days after injury but recovered to preinjury levels by 7 days and was maintained at 14 days (Figure 1Down). Little or no change in {alpha}-tubulin levels were detected in these extracts, which indicated equal protein loading.



View larger version (34K):
[in this window]
[in a new window]
 
Figure 1. Transient downregulation of GATA-6 protein expression in rat carotid arteries after balloon injury. Whole-cell extracts from uninjured (U) and injured arteries were prepared from a pool of 4 or 5 arteries at each time point. Seventy-five microgram lysates were assayed by immunoblot analyses with antibodies against GATA-6 or {alpha}-tubulin.

EMSAs were performed to examine GATA-6 DNA-binding activity in whole cell extracts prepared from injured and noninjured rat carotid arteries. With the use of extracts prepared from an uninjured artery, a diffuse nucleoprotein complex was detected with a radiolabeled duplex oligonucleotide probe that corresponded to the GATA site derived from a mouse {alpha}-globin promoter (Figure 2ADown). This nucleoprotein complex was not detected when the DNA-binding mixture contained a 100-fold molar excess of unlabeled consensus oligonucleotide probe, whereas in a parallel reaction, a 100-fold molar excess of probe that contained a mutation in the GATA consensus sequence was unable to compete for complex formation. The presence of GATA-6 protein in the nucleoprotein complex was demonstrated by the ability to supershift complex with anti–GATA-6 antibodies raised to regions of the GATA-6 protein that were not homologous to the other GATA proteins (Figure 2BDown). Inclusion of preimmune serum did not alter the nucleoprotein complex. Collectively, these data demonstrate that GATA-6 DNA-binding activity can be detected in extracts prepared from rat carotid arteries.



View larger version (101K):
[in this window]
[in a new window]
 
Figure 2. GATA-6 DNA-binding activity in rat carotid arteries is transiently decreased after balloon injury. A, Whole-cell extract from pooled, uninjured arteries was incubated with {gamma}32P-labeled probe to the GATA consensus sequence from the {alpha}-globin promoter. The indicated binding reactions contained a 100-fold molar excess of nonlabeled consensus GATA-6 probe (WT) or a 100-fold molar excess of probe, which contained a mutation in the GATA sequence (MT). Nucleoprotein complexes were detected by EMSA. B, This nucleoprotein complex was diminished and supershifted by incubation with anti–GATA-6 antibody (G6) but not with preimmune serum (PI). C, GATA-6 DNA-binding activity is downregulated at 24 and 72 hours after balloon injury. Whole-cell extracts from pools of 4 or 5 uninjured (U) or injured arteries at the indicated time points were assayed by EMSA.

GATA-6 DNA-binding activity was decreased in extract prepared from arteries at 1 or 3 days after injury compared with uninjured vessels, but DNA-binding activity recovered to preinjury levels at 7 and 14 days after injury (Figure 2CUp). The changes in GATA-6 DNA-binding activity parallel closely the changes in GATA-6 protein levels (Figure 1Up). The same EMSA results were obtained with GATA consensus DNA sequences from the mouse {alpha}–globin promoter (Figure 2Up), the GATA/CEF-1 binding site from the murine cardiac troponin C gene that binds GATA-6,15 or the GATA consensus binding site from the human T-cell receptor {delta} gene27 (data not shown).

Previous work in cultured VSMCs indicated that steady-state GATA-6 transcript levels decreased after mitogen-activated cell proliferation.16 To investigate this regulation in vivo, transcript levels of GATA-6 and GAPDH (as a control) were measured in balloon-injured and uninjured rat carotid arteries by a semiquantitative RT-PCR assay under conditions that ensured a linear accumulation of signal with respect to input RNA and cycle number. An advantage of this RT-PCR approach is that RNA from individual arteries could be analyzed, which allowed a statistical analysis. The results confirmed the Western blotting experiments, which showed that GATA-6 transcript levels (relative to the control GAPDH mRNA) decreased significantly 3 days after balloon injury (Figure 3ADown). At day 3, transcript levels decreased nearly 3-fold (0.37±0.12 relative to 1.0 for uninjured arteries; Figure 3BDown). These results are consistent with a primary effect on the GATA-6 gene at the mRNA level after vessel injury in vivo.



View larger version (38K):
[in this window]
[in a new window]
 
Figure 3. GATA-6 transcript levels are transiently downregulated in rat carotid arteries after balloon injury. A, Examples are shown of autoradiographs used to measure the relative abundance of GAPDH and GATA-6 in RNA isolated from carotid arteries subjected to balloon injury (Test) or contralateral arteries (Control). Samples shown in the left panel are from 3 days after injury. In this example, the GATA-6 transcript level (Test/Control) is 0.26, after normalizing to GAPDH. The panel on the right illustrates a typical control and demonstrates that PCR products accumulate linearly with respect to input RNA. Total RNA used in the RT reaction was 0.5 µg (2 times) or 0.25 µg (1 time). B, Graph plots the relative abundance of GATA-6 transcripts in balloon-injured arteries relative to control contralateral arteries at 1, 3, 7, and 14 days after angioplasty. The data are derived from 3 independent sets of arteries for each time point and are presented as the mean±SEM. The y-axis values are the ratio of transcript levels in the untreated contralateral arteries (designated 1.0) relative to the injured vessel at the indicated time point. *P<0.05 at day 3.

Construction and Characterization of Replication-Defective Adenoviral Vectors Expressing GATA-6 cDNAs
Because the GATA-6 gene is regulated at the transcript level after stimulation of VSMC proliferation, it was reasonable to consider whether forced transcription to restore levels might inhibit intimal hyperplasia in the rat model of balloon injury. For this purpose, replication-defective adenoviral vectors were constructed to express GATA-6 (Ad-GATA6) or a mutant non–DNA-binding GATA-6 (Ad-GATA6{Delta}ZF) that lacks a large portion of the zinc-finger DNA-binding domain (Figure 4ADown). In preliminary cell culture experiments, Western immunoblot analysis of NIH3T3 cells revealed prominent immunoreactive bands that migrate with an apparent molecular weight of 52 kDa in the Ad-GATA6–infected cells and 46 kDa in the Ad-GATA6{Delta}ZF–infected cells, which is consistent with the predicted molecular weight of the wild-type and mutant GATA-6 proteins (Figure 4BDown).



View larger version (37K):
[in this window]
[in a new window]
 
Figure 4. Structure and in vitro characterization of wild-type and mutant GATA-6–encoding adenoviral vectors. A, Structures of the adenoviral vectors encoding the wild-type GATA-6 and mutant GATA-6{Delta}ZF that contains a deletion at the zinc-finger domain. B, Expression of adenovirus-encoded GATA-6 proteins. NIH3T3 fibroblasts were infected with Ad-GATA6 (WT), Ad-GATA6{Delta}ZF, or Ad-ßGal at the MOI of 100. Whole-cell extracts were prepared from the indicated infected cells or uninfected (U) cells and subjected to immunoblot analysis. C, DNA-binding activity of adenovirus-encoded GATA-6. Whole-cell extracts were prepared from infected and noninfected NIH3T3 cells and examined by EMSA. All binding mixtures contained the 32P-labeled probe to the GATA consensus sequence from the {alpha}-globin promoter. The indicated binding reactions also contained a 10- or 100-fold molar excess of nonlabeled consensus GATA-6 probe (wt) or a 100-fold molar excess of probe, which contained a mutation in the GATA sequence (mt). Indicated binding reactions contained anti–GATA-6 antibody (G6) or preimmune serum (PI).

To confirm the expected activity of the wild-type and mutant proteins, whole-cell lysates from NIH3T3 cells infected with Ad-GATA6 were used in gel mobility shift experiments, which showed a significant increase in the predominant nucleoprotein complex (Figure 4CUp, arrowhead) relative to lysates from uninfected cells (the NIH3T3 lysates contain low levels of an endogenous GATA-binding activity). This complex was competed specifically with excess unlabeled target site probe but not by the mutant probe (Figure 4CUp). The inclusion of specific anti–GATA-6 antibodies gave a supershifted complex, whereas preimmune sera had no effect. No increase in specific binding activity was detected in lysates of NIH3T3 cells infected with Ad-GATA6{Delta}ZF or the control virus that expresses ß-galactosidase, Ad-ßgal. Therefore, with respect to DNA-binding activity, these data show that Ad-GATA6 expresses functional GATA-6 protein, whereas Ad-GATA6{Delta}ZF does not.

Previously, we reported that plasmid-encoded GATA-6 inhibits cell growth.19 Thus, FACS analysis was performed to test whether the GATA-6–expressing adenoviral vectors also inhibit cell cycle activity (TableDown). Quiescent VSMCs were transduced with adenoviral constructs and stimulated with high-mitogen media. Ad-GATA6 transduced cells were arrested in G0/G1 phases of the cell cycle, comparable to uninfected quiescent cells. In contrast, FACS analyses revealed that mitogen-stimulated cells transduced with Ad-GATA6{Delta}ZF or Ad-ßgal were comparable to mock-infected, mitogen-stimulated cells. Infection with Ad-GATA6 also led to a corresponding decrease in the proportion of cells in S phase compared with Ad-GATA6{Delta}ZF, Ad-ßGal, or mock-infected cells. These data demonstrate that adenovirus-mediated overexpression of GATA-6 inhibits cell growth in vitro but the GATA-6 mutant lacking the zinc-finger domain does not.


View this table:
[in this window]
[in a new window]
 
Table 1. Cell Cycle Phase

Ad-GATA6 Inhibits Neointima Formation in Balloon-Injured Carotid Arteries
To test the activity of GATA-6 in vivo, the adenoviral constructs were used to deliver wild-type and mutant GATA-6 locally to balloon-injured rat carotid arteries. Immediately after denudation with a balloon catheter, the vessel wall was exposed to adenoviral solution (1.0x109 PFU) for 20 minutes. Arteries were harvested 1 or 3 days afterward to examine protein expression by immunoblot analysis or EMSA or at 2 weeks to assess intimal hyperplasia. Immunoblot analysis revealed that local delivery of Ad-GATA6 partially restores GATA-6 protein levels at the 3-day postinjury time point (Figure 5ADown). Similar results were also observed with extracts prepared from vessels at 1 day after injury (not shown). Gel mobility shift experiments revealed that the injury-induced decrease in GATA-6 DNA-binding activity levels was partially reversed when assessed at day 3 (Figure 5BDown) or day 1 (not shown) postinjury. Therefore, adenovirus-mediated GATA-6 gene transfer results in restoration of GATA-6 expression, although at lower levels relative to uninjured vessels.



View larger version (48K):
[in this window]
[in a new window]
 
Figure 5. Ad-GATA6 partially restores GATA-6 protein expression and DNA-binding activity to preinjury levels in balloon-injured rat carotid arteries. Balloon-injured rat carotid arteries were incubated with Ad-GATA6 or saline for 20 minutes immediately after injury. Whole-cell extracts were prepared from pools of 4 to 5 uninjured or injured and treated vessels. A, Immunoblot of analysis of GATA-6, PCNA, and tubulin protein expression in extracts prepared from uninjured vessels or 3 day after injury vessels that were infected with Ad-GATA6 or mock-infected (saline). B, EMSA of whole cell extracts prepared from uninjured vessels, mock-infected vessels (saline) at 1 and 3 days after injury, and Ad-GATA6-infected vessels at 3 days after injury.

Immunoblot analysis revealed that expression of PCNA, a marker of VSMC proliferation, was suppressed in extracts prepared from Ad-GATA6–infected vessels, relative to saline injected controls (Figure 5AUp). Analyses of PCNA staining of histological sections at 3 days after injury revealed that the expression of PCNA-positive cells in Ad-GATA6–treated vessels was reduced by a factor of 3.2 relative to the saline control (P<0.01), whereas the Ad-ßgal– and Ad-GATA6{Delta}ZF–treated vessels displayed 14% more (not statistically significant) or 9% fewer (not statistically significant) PCNA-positive cells, respectively, than the saline control (data not shown). Therefore, similar to its antiproliferative function in vitro, forced expression of GATA-6 appears to inhibit cell growth in the vessel wall.

Western immunoblot analyses were performed on injured vessels to examine the effects of constitutive GATA-6 expression on markers of smooth muscle cell differentiation. Smooth muscle myosin heavy chain (SM MHC), smooth muscle {alpha}-actin (SM {alpha}-actin), and calponin expression and the ratio of metavinculin to vinculin expression are indicative of smooth muscle cell differentiation in developing vessels and vascular disease.28 As expected, vascular injury downregulated the expression of SM MHC, SM {alpha}-actin, and calponin, whereas the expression of the cyclin-dependent kinase cdk4 did not change (Figure 6Down). Injury also increased the ratio of vinculin to metavinculin expression, which is consistent with reports that this ratio is indicative of VSMC differentiation in adult human tissues.29 30 Infection of vessels with Ad-GATA6 at the time of injury attenuated the downregulation of SM MHC, SM {alpha}-actin, and calponin. In contrast, vinculin was reduced to near preinjury levels by the partial restoration of GATA-6 expression. These data suggest that GATA-6 regulates the differentiated phenotype of VSMCs under conditions that induce intimal lesions.



View larger version (72K):
[in this window]
[in a new window]
 
Figure 6. Ad-GATA6 promotes expression of VSMC-specific proteins in balloon-injured rat carotid arteries. Whole-cell lysates were prepared from pools of 4 to 5 uninjured or injured and treated vessels. Extract protein (10 to 15 µg per lane) was analyzed for expression of SM MHC, SM {alpha}-actin, calponin, metavinculin, vinculin, and cdk4 protein expression by immunoblot analysis. Vessels harvested at 1 day after injury were infected with Ad-GATA-6 or mock-infected (saline) at the time of injury.

Finally, restoration of GATA-6 expression had a significant effect on lesion formation at 2 weeks after injury. Saline-treated arteries and Ad-ßGal–infected arteries had neointima/media (I/M) area ratios of 1.4±0.14 and 1.3±0.13, respectively. In contrast, arteries infected with Ad-GATA6 had an I/M ratio of 0.70±0.13 (P<0.01), which represented a 46% to 50% reduction relative to saline and Ad-ßGal–infected arteries (Figure 7Down). Local delivery of Ad-GATA6{Delta}ZF did not significantly inhibit neointima formation (I/M ratio of 1.2±0.13). Collectively, these data indicate that relatively low levels of GATA-6 expression in the vessel wall can inhibit injury-induced stenosis in the rat carotid model.



View larger version (47K):
[in this window]
[in a new window]
 
Figure 7. Ad-GATA6 inhibits neointima formation in the rat carotid balloon-injured arteries. A, Representative hematoxylin-eosin stained cross section in rat carotid artery 14 days after balloon injury and adenovirus infection (Ad-ßGal or Ad-GATA6). Arrows indicate elastic-lamina stain. B, Histological images from the artery cross sections were projected on a digitizing board and quantitative assessments of intimal and medial area were assessed for saline-, Ad-GATA6–, Ad-GATA6{Delta}ZF–, and Ad-ßgal–treated vessels at 14 days after injury. I/M is shown as mean±SEM. I/M was significantly reduced in Ad-GATA6(WT)–transduced arteries (P<0.01) but not in Ad-GATA6{Delta}ZF– or Ad-ßgal–treated arteries compared with saline-treated controls.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
The VSMCs of the normal adult vessel wall are quiescent and display characteristics of a differentiated phenotype. After injury and growth factor release, VSMCs regress to a less differentiated state and proliferate. This process has been referred to as phenotypic modulation,31 32 and phenotypically modified smooth muscle cells are a hallmark of atherosclerotic and restenotic lesions in humans.33 34 To understand the process that coordinates differentiation and cell cycle activity during VSMC phenotypic modulation, several studies have examined the role of smooth muscle transcription factors that are regulated by mitogen activation.35 36 Previous work has documented that GATA-6 is the predominant GATA factor expressed in VSMCs.15 16 In cultured VSMCs, GATA-6 transcript levels are rapidly and transiently decreased after mitogen stimulation.16

In this study, we examined the role of GATA-6 in the genesis of a proliferative lesion in the blood vessel wall. GATA-6 regulation and function was examined in balloon-injured rat carotid arteries, a well-characterized model that induces robust VSMC proliferation and produces a lesion that partially occludes the lumen of the vessel. Downregulation of the GATA-6 protein was noted at 1 and 3 days after injury, which corresponds to a peak of proliferative activity in medial VSMCs.21 22 Levels of GATA-6 protein returned to normal after 7 days, and this level of expression was maintained at 14 days after injury. At these later time points, medial smooth muscle cell proliferation has ceased, whereas smooth muscle cells at the luminal edge of the lesion continue to proliferate.21 The time course of GATA-6 depletion and recovery was closely paralleled by changes in GATA-6 DNA-binding activity. Furthermore, GATA-6 mRNA levels also decreased and then recovered after balloon injury, which is consistent with the notion that the gene is regulated at the transcriptional level in balloon-injured vessels. This aspect is important because translational controls might preclude restoration of GATA-6 levels by gene transfer techniques. The time course of GATA-6 downregulation and recovery in injured carotid arteries was similar to that of Gax, another mitogen-regulated transcription factor in VSMCs that can inhibit cell growth.26 37

To determine the functional significance of GATA-6 downregulation in vivo, replication-defective adenoviral constructs that expressed functional or nonfunctional GATA-6 cDNAs were constructed and used to deliver these transgenes locally to the sites of vascular injury. Adenovirus-mediated delivery of the wild-type GATA-6 gene inhibited intimal hyperplasia by 50%, relative to a control adenovirus that expressed lacZ, whereas adenovirus-mediated delivery of a mutated GATA-6 cDNA did not inhibit lesion formation. Note that although adenovirus-mediated GATA-6 gene transfer resulted in elevation of GATA-6 protein and DNA-binding activity at 1 and 3 days after injury, preinjury levels were not achieved. Therefore, physiological levels of GATA-6 appear to be critical to determining the size of the injury-induced lesion. In contrast, the efficacy of other gene products for inhibition of vascular lesion progression appears to require extensive overexpression.38 39

GATA-6–mediated inhibition of intimal lesion formation probably results from the ability of this factor to promote VSMC differentiation and inhibit mitogen-activated cell-cycle activity. It has been shown previously that plasmid-mediated overexpression of GATA-6 can inhibit the proliferation of VSMCs and fibroblasts.19 In this study, we show that PCNA expression, a marker of VSMC proliferation, was reduced in the GATA-6-transduced vessels, which suggests that GATA-6 has antiproliferative properties in vivo. The importance of cell-cycle activity during intimal hyperplasia is underscored by the observation that injury-induced lesion formation is inhibited by molecules that can interfere with cell-cycle progression. For example, intimal hyperplasia is inhibited by antisense cdk2 oligonucleotides40 and by overexpression of both the wild-type and mutant forms of the retinoblastoma protein39 41 or the cdk inhibitor p21.38

During VSMC phenotypic modulation, proliferation is accompanied by a reversion of VSMCs to a less differentiated, fibroblast-like state. Thus, it has been suggested that the same subset of transcription factors that regulate cell division might also be important in controlling the expression of tissue-specific genes associated with the differentiated state.35 36 In this study, we have shown that restoration of GATA-6 expression in balloon-denuded arteries attenuates the changes in SM MHC, SM {alpha}-actin, calponin, vinculin, and metavinculin expression that occur with injury-induced VSMC phenotypic modulation. Although direct transcriptional links between GATA-6 and these genes have not been demonstrated to date, many contain consensus WGATAR sequences (GATA-6 binding sites) in their promoters. Of note, vinculin and metavinculin are alternative splice products of a single gene,28 which suggests that GATA-6 can control numerous regulatory processes within VSMCs, including posttranscriptional mechanisms. Surprisingly, the GATA-6-induced VSMC differentiation was not observed when cultured rat or human VSMCs were infected with the Ad-GATA6 construct (T.M., K.W., unpublished observations, 1998). These data suggest that extracellular components present within the intact vessel wall are essential for GATA-6–induced expression of differentiation-specific genes.

Many diseases of the vessel wall are associated with the dedifferentiation and excessive proliferation of VSMCs. In this study, we demonstrated that the levels of GATA-6 transcript, protein, and DNA-binding activities are decreased in the vessel wall after acute injury and that lesion formation is inhibited by the partial restoration of GATA-6 expression. These data indicate that GATA-6 downregulation after injury is an essential feature of the proliferative response to vessel wall injury. Identification of GATA-6 as an endogenous regulator of pathological VSMC proliferation may provide insights about the molecular mechanisms that contribute to vascular lesions and may have implications for the development of new therapies to treat these diseases.


*    Acknowledgments
 
This work was supported by NIH grants HL-50692 and AR-40197 to Dr Walsh. Dr Evans is an Established Investigator of the American Heart Association.

Received August 20, 1998; accepted January 13, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]

2. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Salter LF, Popma JJ, Wong SC, Leon MB. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol. 1995;26:720–724.[Abstract]

3. Dilley RJ, McGeachie JK, Prendergast FJ. A review of the histologic changes in vein-to-artery grafts, with particular reference to intimal hyperplasia. Arch Surg. 1988;123:691–696.[Abstract/Free Full Text]

4. Braun-Dullaeus R, Mann M, Dzau V. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 1998;98:82–89.[Abstract/Free Full Text]

5. Simon MC. Gotta have GATA. Nat Genet. 1995;11:9–11.[Medline] [Order article via Infotrieve]

6. Grépin C, Nemer G, Nemer M. Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development. 1997;124:2387–2395.[Abstract]

7. Grépin C, Robitaille L, Antakly T, Nemer M. Inhibition of transcription factor GATA-4 expression blocks in vitro cardiac muscle differentiation. Mol Cell Biol. 1995;15:4095–4102.[Abstract]

8. Durocher D, Charron F, Warren R, Schwartz R, Nemer M. The cardiac transcription factors Nkx2.5 and GATA-4 are mutual cofactors. EMBO J. 1997;16:5687–5696.[Medline] [Order article via Infotrieve]

9. Durocher D, Nemer M. Combinatorial interactions regulating cardiac transcription. Dev Genet. 1998;22:250–262.[Medline] [Order article via Infotrieve]

10. McGrew M, Bogdanova N, Hasegawa K, Hughes S, Kitsis R, Rosenthal N. Distinct gene expression patterns in skeletal and cardiac muscle are dependent on common regulatory sequences in the MLC1/3 Locus. Mol Cell Biol. 1996;16:4524–4534.[Abstract]

11. Jiang Y, Evans T. The Xenopus GATA-4/5/6 genes are associated with cardiac specification and can regulate cardiac-specific transcription during embryogenesis. Dev Biol. 1996;174:258–270.[Medline] [Order article via Infotrieve]

12. Molkentin JD, Lin Q, Duncan SA, Olson EN. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 1997;11:1061–1072.[Abstract/Free Full Text]

13. Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, Soudais C, Leiden JM. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev. 1997;11:1048–1060.[Abstract/Free Full Text]

14. Jiang Y, Tarzami S, Burch JB, Evans T. Common role for each of the cGATA-4/5/6 genes in the regulation of cardiac morphogenesis. Dev Genet. 1998;22:263–277.[Medline] [Order article via Infotrieve]

15. Morrisey EE, Ip HS, Parmacek MS. GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm. Dev Biol. 1996;177:309–323.[Medline] [Order article via Infotrieve]

16. Suzuki E, Evans T, Lowry J, Truong L, Bell DW, Testa JR, Walsh K. The human GATA-6 gene: structure, chromosomal location and regulation of expression by tissue-specific and mitogen-responsive signals. Genomics. 1996;38:283–290.[Medline] [Order article via Infotrieve]

17. Fornace AJ, Jackman J, Hollander MC, Hoffman-Liebermann B, Liebermann DA. Genotoxic-stress-response genes and growth arrest genes: gadd, MyD, and other genes induced by treatments eliciting growth arrest. Ann N Y Acad Sci. 1992;663:139–153.[Medline] [Order article via Infotrieve]

18. Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell. 1988;54:787–793.[Medline] [Order article via Infotrieve]

19. Perlman H, Suzuki E, Simonson M, Smith RC, Walsh K. GATA-6 induces p21Cip1 expression and G1 cell cycle arrest. J Biol Chem. 1998;273:13713–13718.[Abstract/Free Full Text]

20. Perlman H, Maillard L, Krasinski K, Walsh K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells following balloon injury. Circulation. 1997;95:981–987.[Abstract/Free Full Text]

21. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andrés V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997;80:418–426.

22. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327–333.[Medline] [Order article via Infotrieve]

23. Mader SL. Influence of animal age on the ß-adrenergic system in cultured rat aortic and mesenteric artery smooth muscle cells J Gerontol. 1992;47:B32–B36.

24. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines. Biotechnology. 1992;20:363–390.[Medline] [Order article via Infotrieve]

25. Graham FL, van der Eb AJ. A new technique for assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52:456–467.[Medline] [Order article via Infotrieve]

26. Smith RC, Branellec D, Gorski DH, Guo K, Perlman H, Dedieu JF, Pastore C, Mahfoudi A, Denèfle P, Isner JM, Walsh K. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev. 1997;11:1674–1689.[Abstract/Free Full Text]

27. Ko L, Yamamoto M, Leonard M, George K, Ting P, Engel J. Murine and human T-lymphocyte GATA-3 factors mediate transcription through a cis-regulatory element within the human T-cell receptor delta gene enhancer. Mol Cell Biol. 1991;11:2778–2784.[Abstract/Free Full Text]

28. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487–517.[Abstract/Free Full Text]

29. Brinck U, Mirzaie M, Korabiowska M, Meyer T. Expression rate of vinculin isoforms in human aortocoronary saphenous vein grafts. Int J Cardiol. 1997;59:125–132.[Medline] [Order article via Infotrieve]

30. Glukhova M, Kabakov A, Frid M, Ornatsky O, Belkin A, Mukhin D, Orekhov A, Koteliansky V, Smirnov V. Modulation of human aorta smooth muscle cell phenotype: a study of muscle-specific variants of vinculin, caldesmon, and actin expression. Proc Natl Acad Sci U S A. 1988;85:9542–9546.[Abstract/Free Full Text]

31. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev. 1979;59:1–61.[Free Full Text]

32. Campbell GR, Campbell JH. Phenotypic modulation of smooth muscle cells in primary culture. In: Campbell JH, Campbell GR, eds. Vascular Smooth Muscle in Culture. Boca Raton, Fla: CRC Press Inc; 1987:I39–I55.

33. Aikawa M, Sivam PN, Kuro-o M, Kimura K, Nakahara K, Takewaki S, Ueda M, Yamaguchi H, Yazaki Y, Periasamy M, Nagai R. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res. 1993;73:1000–1012.[Abstract/Free Full Text]

34. Chen YH, Chen YL, Lin SJ, Chou CY, Mar GY, Chang MS, Wang SP. Electron microscopic studies of phenotypic modulation of smooth muscle cells in coronary arteries of patients with unstable angina pectoris and postangioplasty restenosis. Circulation. 1997;95:1169–1175.[Abstract/Free Full Text]

35. Walsh K, Perlman H. Molecular strategies to inhibit restenosis: modulation of the vascular myocyte phenotype. Semin Interv Cardiol. 1996;1:173–179.[Medline] [Order article via Infotrieve]

36. Gorski DH, Walsh K. Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. Cardiovasc Res. 1995;30:585–592.[Medline] [Order article via Infotrieve]

37. Weir L, Chen D, Pastore C, Isner JM, Walsh K. Expression of GAX, a growth-arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. J Biol Chem. 1995;270:5457–5461.[Abstract/Free Full Text]

38. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260–2268.

39. Smith RC, Wills KN, Antelman D, Perlman H, Truong LN, Krasinski K, Walsh K. Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation. 1997;96:1899–1905.[Abstract/Free Full Text]

40. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leynen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458–1464.

41. Chang MW, Barr E, Seltzer J, Jiang Y, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518–522.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
S. M. Shirvani, L. Mookanamparambil, M. F. Ramoni, and M. T. Chin
Transcription factor CHF1/Hey2 regulates the global transcriptional response to platelet-derived growth factor in vascular smooth muscle cells
Physiol Genomics, June 19, 2007; 30(1): 61 - 68.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Takeji, T. Moriyama, S. Oseto, N. Kawada, M. Hori, E. Imai, and T. Miwa
Smooth Muscle {alpha}-Actin Deficiency in Myofibroblasts Leads to Enhanced Renal Tissue Fibrosis
J. Biol. Chem., December 29, 2006; 281(52): 40193 - 40200.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
B. P. Herring, O. El-Mounayri, P. J. Gallagher, F. Yin, and J. Zhou
Regulation of myosin light chain kinase and telokin expression in smooth muscle tissues
Am J Physiol Cell Physiol, November 1, 2006; 291(5): C817 - C827.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Zhou, G. Hu, and B. P. Herring
Smooth Muscle-Specific Genes Are Differentially Sensitive to Inhibition by Elk-1
Mol. Cell. Biol., November 15, 2005; 25(22): 9874 - 9885.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. A. Deaton, C. Su, T. G. Valencia, and S. R. Grant
Transforming Growth Factor-{beta}1-induced Expression of Smooth Muscle Marker Genes Involves Activation of PKN and p38 MAPK
J. Biol. Chem., September 2, 2005; 280(35): 31172 - 31181.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Yin and B. P. Herring
GATA-6 Can Act as a Positive or Negative Regulator of Smooth Muscle-specific Gene Expression
J. Biol. Chem., February 11, 2005; 280(6): 4745 - 4752.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. J. Lepore, T. P. Cappola, P. A. Mericko, E. E. Morrisey, and M. S. Parmacek
GATA-6 Regulates Genes Promoting Synthetic Functions in Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 309 - 314.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
K. M. Mann, J. L. Ray, E. S. Moon, K. M. Sass, and M. R. Benson
Calcineurin initiates smooth muscle differentiation in neural crest stem cells
J. Cell Biol., May 24, 2004; 165(4): 483 - 491.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. Liu, M. Ikegami, M. T. Stahlman, C. R. Dey, and J. A. Whitsett
Inhibition of alveolarization and altered pulmonary mechanics in mice expressing GATA-6
Am J Physiol Lung Cell Mol Physiol, December 1, 2003; 285(6): L1246 - L1254.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. M. Taylor and C. A. McNamara
Regulation of Vascular Smooth Muscle Cell Growth: Targeting the Final Common Pathway
Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1717 - 1720.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. J. Suzuki, R. M. Day, C. C. Tan, T. H. Sandven, Q. Liang, J. D. Molkentin, and B. L. Fanburg
Activation of GATA-4 by Serotonin in Pulmonary Artery Smooth Muscle Cells
J. Biol. Chem., May 2, 2003; 278(19): 17525 - 17531.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. S. Kumar and G. K. Owens
Combinatorial Control of Smooth Muscle-Specific Gene Expression
Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 737 - 747.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Abe, K. Hasegawa, H. Wada, T. Morimoto, T. Yanazume, T. Kawamura, M. Hirai, Y. Furukawa, and T. Kita
GATA-6 Is Involved in PPAR{gamma}-Mediated Activation of Differentiated Phenotype in Human Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 404 - 410.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Yaar, L. M. Cataldo, A. Tzatsos, C. E. Francis, Z. Zhao, and K. Ravid
Regulation of the A3 Adenosine Receptor Gene in Vascular Smooth Muscle Cells: Role of a cAMP and GATA Element
Mol. Pharmacol., November 1, 2002; 62(5): 1167 - 1176.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. V. Ennezat, S. L. Malendowicz, M. Testa, P. C. Colombo, A. Cohen-Solal, T. Evans, and T. H. LeJemtel
Physical training in patients with chronic heart failure enhances the expression of genes encoding antioxidative enzymes
J. Am. Coll. Cardiol., July 1, 2001; 38(1): 194 - 198.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. D. Ellis, Q. Chen, P. J. Barker, J. C. Metcalfe, and P. R. Kemp
Nov Gene Encodes Adhesion Factor for Vascular Smooth Muscle Cells and Is Dynamically Regulated in Response to Vascular Injury
Arterioscler. Thromb. Vasc. Biol., August 1, 2000; 20(8): 1912 - 1919.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. R. Kibbe, T. R. Billiar, and E. Tzeng
Gene Therapy for Restenosis
Circ. Res., April 28, 2000; 86(8): 829 - 833.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. M. Miano, M. J. Carlson, J. A. Spencer, and R. P. Misra
Serum Response Factor-dependent Regulation of the Smooth Muscle Calponin Gene
J. Biol. Chem., March 24, 2000; 275(13): 9814 - 9822.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. D. Molkentin
The Zinc Finger-containing Transcription Factors GATA-4, -5, and -6. UBIQUITOUSLY EXPRESSED REGULATORS OF TISSUE-SPECIFIC GENE EXPRESSION
J. Biol. Chem., December 8, 2000; 275(50): 38949 - 38952.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mano, T.
Right arrow Articles by Walsh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mano, T.
Right arrow Articles by Walsh, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Carotid Artery Disease
Related Collections
Right arrow Gene expression
Right arrow Smooth muscle proliferation and differentiation